In our study, we found that the ADAM-12 level was significantly increased in SCLC patients compared with normal controls and in patients with extensive disease compared to those with limited disease, suggesting that ADAM-12 might be as an effective diagnostic and prognostic marker. This evidence concerns the gene ADAM12 and small cell lung carcinoma.